DANFORTH ADVISORS NAMES ROBERT DICKEY IV MANAGING DIRECTOR, MID ATLANTIC REGION

Published: Sep 12, 2018

https://ci5.googleusercontent.com/proxy/ndnETYcR5Vm1JxDE4TGhexYGAxWxbc9iuTZpClDyrE_UglcvmsMS01_A0qPjyqDL4IgUNYyT3-Irj8sW7yciqWVMCmxVryqFgrIvi8knuT5Fd2QmeaJCKM-vObM=s0-d-e1-ft#http://boston.big3bio.com/wp-content/uploads/2014/08/danforth-logo.png


Somerville, MA – September 11, 2018 – Danforth Advisors, LLC, specialists in accounting, finance support and strategy for life science and healthcare companies, today announced additional regional leadership and support with the appointment of Robert Dickey IV as Managing Director, Mid Atlantic Region. An experienced life science executive and former investment banker, Mr. Dickey will direct the firm’s strategy and service to clients in the region’s fast-growing life science clusters.

“Danforth has assembled a first-rate team with deep expertise in accounting, finance strategy and operations for life science companies, allowing both start-ups and growth-stage clients to benefit from the highest level of talent in a flexible and capital-efficient way,” said Mr. Dickey. “I look forward to expanding the firm’s reach and resources in the mid Atlantic cities where demand for such expertise is on the rise.”

“We are excited to welcome Rob and solidify our commitment to the life science communities in the mid Atlantic region,” said Daniel E. Geffken, Co-founder and Managing Director of Danforth. “We’ve amassed tremendous knowledge on the business side of life science, and pride ourselves on filling a valuable role within the ecosystems of both emerging and well-established life science hubs.” 

Mr. Dickey is an accomplished C-level executive with more than 20 years of experience leading life science and medical device companies, both private and public, ranging from early-stage development to commercial operations. Prior to joining Danforth, he served as CFO to multiple companies, including Motif Bio (NASDAQ/AIM: MTFB), Tyme Technologies, Inc. (NASDAQ: TYME), BeyondSpring Pharmaceuticals, Inc. (NASDAQ: BYSI) and NeoStem, Inc. – now Caladrius Biosciences, Inc. (NASDAQ: CLBS). He previously spent nearly 20 years in investment banking at Lehman Brothers and Legg Mason.

Mr. Dickey is experienced in all stages of the corporate life cycle, including start-up operations, high growth, turnarounds and exit strategies. His expertise includes building organizations, public and private financings, mergers and acquisitions, partnering/licensing transactions, project management and Chapter 11 reorganizations, as well as interactions with boards, venture capitalists, shareholders and Wall Street. He holds an AB from Princeton University and a MBA from The Wharton School, University of Pennsylvania.

About Danforth Advisors
Danforth specializes in accounting, finance support and strategy for life science and healthcare companies. Our services range from execution of day-to-day finance and accounting functions to strategic CFO advisory, capital raising, financial and operational planning and analysis, and transactional support and execution for public offerings, mergers and acquisitions. Clients at all phases of the corporate lifecycle can take advantage of these services on a part-time, interim or project basis, scaling as needed. Danforth was founded in 2011 and has served over 300 life science and digital health companies with our unique, modular approach. Additional information is available at www.danforthadvisors.com.


Media Contact:
Felicia Krupps
fkrupps@danforthadvisors.com

Felicia Krupps | Associate Director of Marketing & Communications

617-418-9434 | fkrupps@danforthadvisors.com

www.danforthadvisors.com | Follow us @DanforthAdvisor


 

Back to news